Where ADCs Fit in the Endometrial Cancer Landscape

Shannon N. Westin, MD, MPH, FACOG, FASCO, of The University of Texas MD Anderson Cancer Center, opens a discussion on antibody-drug conjugates (ADCs) in endometrial cancer with Angeles Alvarez Secord, MD, MHSc, of Duke Cancer Institute, and Bradley R. Corr, MD, of University of Colorado Cancer Center. Westin notes that new targets such as B7-H4, CDH6, HER2, and TROP2 are being studied alongside folate receptor alpha, and that clinicians must now weigh early-phase data against registration trials and decide where ADCs fit relative to immunotherapy and PARP inhibitors. Corr says immunotherapy is the current standard and expects ADCs to enter the recurrent setting first, then move into adjuvant, upfront, and maintenance use. Secord explains that because most patients now receive immunotherapy in the front line, the second-line strategy has changed, and that is where ADCs are falli